{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:31:41Z","timestamp":1738819901163,"version":"3.37.0"},"reference-count":0,"publisher":"AccScience Publishing","issue":"1","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MI"],"abstract":"<jats:p>Typhoid fever, caused by Salmonella Typhi, remains a significant global public health concern, with an estimated 11 &amp;ndash; 20 million cases annually. Vaccines are critical to controlling typhoid fever. Widespread vaccination diminishes the emergence of antibiotic-resistant strains of S. Typhi. The economic benefits of vaccination are also substantial, as the costs of treating typhoid fever and its complications can be significant. Ty21a&amp;reg;, a killed whole-cell vaccine, and Vivotif&amp;reg;, a live-attenuated vaccine, have been available for decades but have relatively short durations of action and only provide partial protection. Vi polysaccharide-conjugate vaccines have improved the durability of protection, but there is still room for improvement. Typhax&amp;trade;, a novel alternative to traditional conjugate vaccines, utilizes Vi polysaccharide that is non-covalently entrapped in a poly-L-lysine and CRM197 protein matrix crosslinked by glutaraldehyde. When formulated with Advax-CpG&amp;trade; adjuvant, Typhax demonstrated promising results in a range of animal models including mice, rabbits, and non-human primates in which it induces high and sustained serum anti-Vi immunoglobulin G and serum bactericidal activity, without any safety or reactogenicity issues. This novel vaccine approach offers the potential for a low-cost, more effective, and durable vaccine against typhoid fever, avoiding the need for frequent booster doses.<\/jats:p>","DOI":"10.36922\/mi.4497","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T09:46:52Z","timestamp":1735552012000},"page":"92","source":"Crossref","is-referenced-by-count":0,"title":["Progress in the development of an Advax-adjuvanted protein capsular matrix vaccine against typhoid fever"],"prefix":"10.36922","volume":"2","author":[{"given":"Nikolai","family":"Petrovsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin P.","family":"Killeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22835","published-online":{"date-parts":[[2024,10,4]]},"container-title":["Microbes &amp; Immunity"],"original-title":[],"link":[{"URL":"https:\/\/api-journal.accscience.com\/uploads\/file\/20250128\/0ba2139e5a26eba55626326b98ba627c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api-journal.accscience.com\/uploads\/file\/20250128\/0ba2139e5a26eba55626326b98ba627c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T01:46:07Z","timestamp":1738806367000},"score":1,"resource":{"primary":{"URL":"https:\/\/accscience.com\/journal\/MI\/2\/1\/10.36922\/mi.4497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,28]]}},"URL":"https:\/\/doi.org\/10.36922\/mi.4497","relation":{},"ISSN":["3041-0886","3029-2883"],"issn-type":[{"type":"print","value":"3041-0886"},{"type":"electronic","value":"3029-2883"}],"subject":[],"published":{"date-parts":[[2024,10,4]]}}}